Navidea Biopharmaceuticals, Inc.
- Industry Medical Appliances & Equipment
- Sector Healthcare
- Market Cap
- Earnings
About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
NAVB
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Navidea Biopharm GAAP EPS of -$0.11
- Navidea stock soars ~25% on upcoming US patent linked to cancer drug pipeline
- Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.07M
- Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.08M
- Navidea Biopharm GAAP EPS of -$0.10, revenue of $0.06M
- Navidea biopharmaceuticals secures additional bridge loan funding of 1M
- Navidea Biopharm GAAP EPS of -$0.10
- Navidea reports initial data from phase 2b study of imaging agent in rheumatoid arthritis patients
- Navidea stock soars ~20%, to get patents in US, Japan
- Navidea Biopharma rises 16% on Indian approval for Lymphoaim
- Navidea receives NYSE American acceptance letter; secures $2.5M bridge loan
- Navidea stock falls 13% after dismal Q4 results
- Navidea Biopharm GAAP EPS of -$0.12, revenue of $0.05M
- Navidea in research pact to evaluate Tc99m tilmanocept as a prognostic marker
- Navidea gets notice on listing noncompliance; settles Platinum lawsuit
- Navidea Biopharma ends stock purchase agreement
- Navidea Biopharm EPS beats by $0.03
- Navidea Biopharm Q3 2021 Earnings Preview
- Navidea Biopharmaceuticals CEO Jed Latkin resigns
- Navidea Biopharmaceuticals CEO-CFO Jed Latkin resigns
